Liver-directed drugs for transthyretin-mediated amyloidosis

Brannagan, T. H., Berk, J. L., Gillmore, J. D., Maurer, M. S., Waddington‐Cruz, M., Fontana, M., Masri, A., Obici, L., Brambatti, M., Baker, B. F., Hannan, L. A., Buchele, G., Viney, N. J., Coelho, T., & Nativi‐Nicolau, J. (2022). Liver‐directed drugs for transthyretin‐mediated amyloidosis. Journal of the Peripheral Nervous System, 27(4), 228–237. Portico. https://doi.org/10.1111/jns.12519
Authors:
Thomas H Brannagan
John L Berk
Julian D Gillmore
Mathew S Maurer
Márcia Waddington-Cruz
Marianna Fontana
Ahmad Masri
Laura Obici
Michela Brambatti
Brenda F Baker
Lisa A Hannan
Gustavo Buchele
Nick J Viney
Teresa Coelho
Jose Nativi-Nicolau
Affiliated Authors:
Thomas H Brannagan
Mathew S Maurer
Columbia Affiliation:
Subjects:
Amyloid Neuropathies, Familial (MeSH)
Prealbumin (MeSH)
Author Keywords:
attr
crispr
rnai
amyloid
antisense therapy
cardiomyopathy
gene editing
polyneuropathy
sirna
silencer
elink
Publication Type:
Article
Unique ID:
10.1111/jns.12519
PMID:
36345805
DOI:
10.1111/jns.12519
Journal:
Journal of the Peripheral Nervous System
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: